  |
Access your linked article here:Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
|
|
| TO EXPLORE NEWSRX SOLUTIONS, CLICK HERE: | ||
Financial
Asset Managers Corporate Finance Hedge Funds Private Equity Traders Wealth Managers Knowledgeable |
Healthcare
Clinicians Employers Government Health Plans Hospital / Provider Pharmaceuticals Knowledgeable |
Scientific
Academics Engineers Librarians/Educators Researchers Scientists Journalists Knowledgeable |
Technology
Computer Designers Software Programmers Network Engineers Communications Engrs. Internet / intranet Engrs. Artificial Intelligence Knowledgeable |
Legal/Regulatory
Government Attorneys Law Firm Managers Litigators Librarians / Educators Academics Knowledgeable |
Business
Accountants / Auditors Librarians / Educators Media Marketers PR Firms Information Analysts Knowledgeable |